Trials / Completed
CompletedNCT05550909
Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
A Five-arm Trial Comparing Artesunate-amodiaquine and Artemether-lumefantrine-amodiaquine With or Without Single-dose Primaquine to Reduce P. Falciparum Transmission in Mali
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- London School of Hygiene and Tropical Medicine · Academic / Other
- Sex
- All
- Age
- 10 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine-amodiaquine (ALAQ) with and without a single dose of 0.25mg/kg primaquine (PQ). Outcome measures will include infectivity to mosquitoes at 2, 7 and 14 days after treatment, gametocyte density throughout follow-up, and safety measures including haemoglobin density and the frequency of adverse events.
Detailed description
Full protocol available on request
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Artesunate-amodiaquine combination | Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines |
| DRUG | Primaquine Phosphate | The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer. |
| DRUG | Artemether-lumefantrine | Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines |
| DRUG | Amodiaquine | Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days. |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2022-12-30
- Completion
- 2023-01-26
- First posted
- 2022-09-22
- Last updated
- 2024-10-01
Locations
1 site across 1 country: Mali
Source: ClinicalTrials.gov record NCT05550909. Inclusion in this directory is not an endorsement.